GlassScriptPhysician profile
Matthew Yanus
NPI 1801472998
$3,178.30
in general payments reported to CMS, 2019-2025
23 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.16 · 2023: $1,278 · 2024: $1,556 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $368.75 | 2023-2024 | Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $347.00 | 2024-2025 | |
| Argenx US, INC. | $298.28 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $292.77 | 2023-2025 | Hizentra |
| Abbvie INC. | $247.48 | 2023-2024 | Botox |
| Takeda Pharmaceuticals U.S.A., INC. | $240.46 | 2023-2025 | Hyqvia, Gammagard |
| Genentech USA, INC. | $211.08 | 2023-2025 | Evrysdi, Activase, Ocrevus |
| Astrazeneca Pharmaceuticals LP | $176.16 | 2023-2025 | Andexxa, Wainua |
| Genzyme Corporation | $169.67 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $136.13 | 2024 | Nuplazid, Daybue |
| Janssen Pharmaceuticals, INC | $107.53 | 2024 | Xarelto |
| Tanabe Pharma America, INC. | $97.99 | 2023-2025 | Radicava |
| Otsuka America Pharmaceutical, INC. | $78.44 | 2023 | Nuedexta |
| Biogen, INC. | $74.98 | 2023-2024 | Vumerity, Tysabri |
| Emd Serono, INC. | $73.46 | 2022-2023 | Mavenclad |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.28 | 2024 | Uplizna |
| Alexion Pharmaceuticals, INC. | $60.62 | 2024 | Ultomiris |
| Pfizer INC. | $30.00 | 2023 | |
| Boston Scientific Corporation | $25.70 | 2025 | Accolade Sr |
| Neurelis, INC. | $23.27 | 2023 | Valtoco |
| Esperion Therapeutics, INC. | $19.24 | 2023 | Nexletol |
| Microtransponder, INC. | $13.84 | 2023 | |
| Grifols USA, LLC | $13.17 | 2023 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Yanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.